Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04147234 · ClinicalTrials.gov registry record · Phase 1
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04147234 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 42 participants.
The verdict
NCT04147234, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines may help the immune system fight cancer. In this study, BI 1387446 is given to humans for the first time. The purpose of this study is to find out the highest dose of BI 1387446 alone and in combination with BI 754091 the participants can tolerate. BI 1387446 is injected directly into the tumour. Participants get BI 1387446 injections every week at the beginning and then every 3 weeks. Some participants get BI 754091 in addition to BI 1387446. BI 754091 is given as an infusion into a vein every 3 weeks. As long as they benefit from treatment and can tolerate it, participants can stay in the study for up to 2 years and 8 months. During this time, they visit the study site regularly. At these visit, doctors record any unwanted effects. The doctors also regularly check participants' health.
Interventions
- DRUG BI 754091
- DRUG BI 1387446 50 μg
- DRUG BI 1387446 100 μg
- DRUG BI 1387446 200 μg
- DRUG BI 1387446 400 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04147234
The ClinicalTrials.gov registry entry for NCT04147234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BI 754091 is the first listed.
NCT04147234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04147234 about?
NCT04147234 is a clinical study titled "A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)". This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines may help the immune system fight cancer. In this study, BI 1387446 is given to humans for the first time. The pur...
What is the current status of trial NCT04147234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-08-03. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT04147234?
The interventions under investigation include: BI 754091 (DRUG), BI 1387446 50 μg (DRUG), BI 1387446 100 μg (DRUG), BI 1387446 200 μg (DRUG), BI 1387446 400 μg (DRUG).
Who is sponsoring clinical trial NCT04147234?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.